Nerve disruption with chemoimmunotherapy for advanced tongue cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether a procedure that disrupts the lingual nerve can help make chemotherapy and immunotherapy work better for tongue cancer before surgery. If you have advanced tongue cancer and are scheduled for this kind of treatment, this study might be a good fit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years
- Confirmed tongue cancer that has grown deeply (stage T3 or T4) but has not spread to other parts of the body
- Willing to receive two cycles of chemotherapy and immunotherapy before surgery, then have the tumor removed
- No active infections, serious heart or lung conditions, or poorly controlled diabetes
- Adequate kidney, liver, and blood cell function, as determined by blood and urine tests
- No prior tongue cancer or other tongue tumors in the last 5 years, and no organ transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help treat advanced mouth cancer. It aims to shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy before surgery improves outcomes for people with advanced laryngeal or hypopharyngeal cancer. The treatment is given before your planned total laryngectomy, and the goal is to shrink the tumor and potentially improve long-term results.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
Hear when a new Tongue Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.